TB-500 / Thymosin Beta-4 (5 mg Vial) Dosage Protocol
TB-500 is a synthetic peptide fragment corresponding to the active region of Thymosin Beta-4 (TĪ²4), a naturally occurring 43-amino-acid peptide found in virtually all human cells. Research focuses on its roles in actin regulation, cell migration, angiogenesis, and tissue repair.
ā” Quickstart Highlights
Dosing & Reconstitution Guide
Standard Protocol: Loading + Maintenance (2 mL = 2.5 mg/mL)
Route: Subcutaneous | Frequency: 2ā3Ć per week
| Phase | Weekly Total | Per Injection | Frequency | U-100 Units |
|---|---|---|---|---|
| Loading (Weeks 1ā4) | 4ā5 mg | 2.0ā2.5 mg | Twice weekly | 80ā100 units (0.8ā1.0 mL) |
| Maintenance (Weeks 5ā12) | 2ā2.5 mg | 2.0ā2.5 mg | Once weekly | 80ā100 units (0.8ā1.0 mL) |
| Ongoing Maintenance | 2 mg | 2.0 mg | Once monthly | 80 units (0.8 mL) |
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water into a sterile insulin syringe.
- Inject slowly down the inside glass wall of the vial; avoid foaming.
- Gently swirl or roll until fully dissolved. Do not shake.
- Label with reconstitution date. Refrigerate at 2ā8Ā°C, protected from light. Use within 28 days.
Supplies Planning
| Item | 6 Weeks (Loading) | 12 Weeks (Load + Maint.) |
|---|---|---|
| TB-500 vials (5 mg each) | 5ā6 vials | 7ā8 vials |
| Insulin syringes (U-100, 1 mL) | 12ā16 | 20ā28 |
| Bacteriostatic water (10 mL) | 2 Ć 10 mL | 2ā3 Ć 10 mL |
| Alcohol swabs | 1 Ć 100-pack | 1ā2 Ć 100-pack |
Mechanism of Action
Thymosin Beta-4 is a G-actin sequestering peptide found in high concentrations in platelets, white blood cells, and many other cell types. Its primary function is regulating actin polymerization ā the process by which actin monomers assemble into filaments critical for cell structure and motility.
In injury contexts, TB-500's key proposed mechanisms include:
- Actin regulation: Upregulates Ī²4-thymosin expression, facilitating cell migration to sites of injury.
- Angiogenesis: Promotes blood vessel formation, supporting nutrient delivery to damaged tissue.
- Anti-inflammatory action: Downregulates pro-inflammatory cytokines, reducing local inflammation.
- Systemic distribution: Unlike purely locally-acting peptides, TB-500 distributes systemically, enabling remote healing ā which is why loading protocols are used to achieve therapeutic tissue concentrations.
The systemic mechanism is why TB-500 protocols use loading phases followed by maintenance ā the goal is to build and then sustain tissue concentrations throughout the body, not just at the injection site.
Research Findings & Safety Profile
- Preclinical studies demonstrate accelerated healing of muscle, tendon, ligament, cornea, and cardiac tissue in animal models.
- Human tolerability studies report mild adverse events at doses up to 1,260 mg in clinical evaluation contexts.
- TB-500 is prohibited by WADA in all competitive sports contexts.
- Possible mild side effects: injection-site reactions, transient fatigue or lethargy, rare nausea.
- Long-term human efficacy data remain limited; all clinical extrapolations are from preclinical models.
Storage
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | ā20Ā°C (ā4Ā°F) | Up to 24 months |
| Reconstituted | 2ā8Ā°C (35ā46Ā°F) | Up to 28 days; avoid freeze-thaw |